The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer
Abstract
EGFr/HER1 and c‐erbB‐2/HER2 expression are associated with poor prognosis in breast cancer. The type I receptor tyrosine kinase (RTK) family to which they belong has four members (HER1–4). In this study, expression of HER1–4 and oestrogen receptor (ER) expression were determined by immunohistochemistry in 220 breast carcinomas. Elevated expression of HER1 was observed in 16.4%, HER2 in 22.8%, HER3 in 17.5%, and HER4 in 11.9% of these tumours. Patients whose tumours overexpressed HER1, 2 or 3 had reduced survival (p = <0.001), whereas those whose tumours overexpressed HER4 had increased survival (p = 0.013); 38.6% of cases overexpressed one or more of HER1, 2 or 3. HER4 was rarely overexpressed with other HERs (1.4% of cases). Cox's multiple regression analysis demonstrated that overexpression of HER1/2/3, HER4, and standard prognostic indicators independently affected survival. HER1–3 expression was related to ER negativity (p < 0.0001, χ 2). Patients with ER‐positive, HER1–3‐positive tumours had a significantly poorer survival (p < 0.001) than those with ER‐positive/HER‐negative or HER4‐positive tumours. Expression of HER RTKs displays complex interactions between different family members. There is a strong interaction, in terms of survival, between HER expression and ER expression. The development of HER‐targeted agents (eg Herceptin, Iressa), and agents targeted at the downstream signalling pathways, therefore provides new possibilities in the treatment of breast cancer. Copyright © 2003 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Ullrich, A., Coussens, L., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W., Lee, J., Yarden, Y., Libermann, T. A., Schlessinger, J., et al. (1984) · Nature · doi:10.1038/309418a0 · Cited by 2,752
Olayioye, M. A. (2000) · The EMBO Journal · doi:10.1093/emboj/19.13.3159 · Cited by 2,434
Coussens, L., Yang-Feng, T. L., Liao, Y.-C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., et al. (1985) · Science · doi:10.1126/science.2999974 · Cited by 1,814
Graus-Porta, D. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1647 · Cited by 1,590
The EGFR family and its ligands in human cancer
Yarden, Y. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00230-1 · Cited by 1,587
Phosphorylation and Regulation of Raf by Akt (Protein Kinase B)
Zimmermann, S., & Moelling, K. (1999) · Science · doi:10.1126/science.286.5445.1741 · Cited by 1,078
Ellis, M. J., Coop, A., Singh, B., Mauriac, L., Llombert-Cussac, A., Jänicke, F., Miller, W. R., Evans, D. B., Dugan, M., Brady, C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3808 · Cited by 1,060
Cited by
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come
Yingchoncharoen, P., Kalinowski, D. S., & Richardson, D. R. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012070 · Cited by 744
A Central Role for HER3 in HER2 -Amplified Breast Cancer: Implications for Targeted Therapy
Lee-Hoeflich, S. T., Crocker, L., Yao, E., Pham, T., Munroe, X., Hoeflich, K. P., Sliwkowski, M. X., & Stern, H. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0380 · Cited by 629
Abd El‐Rehim, D. M., Ball, G., Pinder, S. E., Rakha, E., Paish, C., Robertson, J. F. R., Macmillan, D., Blamey, R. W., & Ellis, I. O. (2005) · International Journal of Cancer · doi:10.1002/ijc.21004 · Cited by 606
Schiff, R., Massarweh, S. A., Shou, J., Bharwani, L., Mohsin, S. K., & Osborne, C. K. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-031212 · Cited by 462
The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
Hsu, J. L., & Hung, M.-C. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9649-6 · Cited by 445
Metadata
- Authors
- Witton, C. J., Reeves, J. R., Going, J. J., Cooke, T. G., & Bartlett, J. M.
- Venue
- The Journal of Pathology
- Publisher
- Wiley
- Published
- 2003-03-31
- Volume
- 200
- Issue
- 3
- Pages
- 290-297
- ISSN
- 0022-3417 (ISSN-L)
- 1096-9896
- OpenAlex
- W2090855460
- Cited by
- 590
- References
- 53
- FWCI
- 10.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer. https://app.cochat.ai/papers/10.1002/path.1370
- The paper
- Witton, C. J., Reeves, J. R., Going, J. J., Cooke, T. G., & Bartlett, J. M. (2003). Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer. The Journal of Pathology. https://doi.org/10.1002/path.1370
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.